Canaccord Genuity Group Reiterates “Buy” Rating for Celldex Therapeutics (NASDAQ:CLDX)
Celldex Therapeutics (NASDAQ:CLDX – Get Free Report)‘s stock had its “buy” rating restated by Canaccord Genuity Group in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $62.00 price objective on the biopharmaceutical company’s stock. Canaccord Genuity Group’s price target points to a potential upside of 139.20% from the stock’s current […]
More Stories
Trump Says Minnesota Officials Will Face ‘Day of Reckoning’ Amid Protests
By Jack Phillips President Donald Trump on Tuesday warned that state officials in Minnesota would face a “DAY OF RECKONING...
US Holiday Spending Jumped in December, Signaling Consumer Strength Into 2026
By Tom Ozimek American consumers closed out the holiday season with a strong December spending surge, adding to evidence that...
US Embassy Warns American Citizens Still in Iran to Leave ‘Now’
By Jack Phillips The U.S. State Department on Monday evening sent a warning to any Americans who are still remaining...
House Panel to Initiate Contempt Proceedings Against Bill Clinton, Comer Says
By Nathan Worcester WASHINGTON—House Oversight Committee Chairman James Comer (R-Ky.) said that his committee will move to hold President Bill...
Pentagon Injects $1 Billion Into L3Harris to Boost Missile Motor Output
By Tom Ozimek The U.S. government will invest $1 billion in L3Harris Technologies’ rocket motor business, a rare direct-to-supplier partnership...
Top Miro Alternatives in 2026 | Free Competitors of Miro for Startups
Looking for an alternative to Miro? Don’t worry, I’ll share a list of tools that are better than Miro. This...